Profile data is unavailable for this security.
About the company
ReNeuron Group plc is a United Kingdom-based clinical-stage stem cell company. The Company is engaged in the development of stem cell therapies targeting areas of unmet or poorly met medical need. It has developed a stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several exosome producer cell lines, its CustomEX platform can be optimized for specific tissue targets and payloads, leading to improvements in therapeutic outcome and a reduction in off-target effects. It offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, it has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
- Revenue in GBP (TTM)249.00k
- Net income in GBP-5.07m
- Incorporated2005
- Employees34.00
- LocationReNeuron Group PLCPencoed Business ParkBRIDGEND CF35 5HYUnited KingdomGBR
- Phone+44 203 819 8400
- Fax+44 148 353 4864
- Websitehttps://www.reneuron.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ovoca Bio PLC | 0.00 | -4.30m | 1.11m | 5.00 | -- | 0.5251 | -- | -- | -0.0527 | -0.0485 | 0.00 | 0.0238 | 0.00 | -- | -- | 0.00 | -79.30 | -25.19 | -94.61 | -27.65 | -- | -- | -- | -- | 6.55 | -1,019.80 | 0.00 | -- | -- | -- | 9.05 | -- | -- | -- |
| ReNeuron Group Plc | 249.00k | -5.07m | 1.93m | 34.00 | -- | 0.7966 | -- | 7.75 | -0.0888 | -0.0888 | 0.0044 | 0.0424 | 0.0246 | -- | 0.6442 | 7,323.53 | -50.10 | -43.12 | -101.09 | -58.50 | -- | -- | -2,037.35 | -714.73 | -- | -- | 0.1247 | -- | 31.51 | 65.26 | 44.18 | -- | -1.31 | -- |
| Fusion Antibodies PLC | 1.58m | -2.84m | 2.96m | 50.00 | -- | 1.27 | -- | 1.87 | -0.0861 | -0.0861 | 0.0436 | 0.0245 | 0.5229 | 3.15 | 1.88 | 31,580.00 | -93.94 | -31.29 | -130.56 | -37.72 | -7.41 | 42.58 | -179.67 | -48.25 | 2.32 | -- | 0.0313 | -- | -39.55 | 1.52 | -116.33 | -- | -23.83 | -- |
| ValiRx Plc | 9.60k | -2.04m | 3.31m | 8.00 | -- | 0.7948 | -- | 344.66 | -0.0201 | -0.0201 | 0.00009 | 0.0315 | 0.0027 | -- | 0.0682 | -- | -59.88 | -50.57 | -58.27 | -54.77 | 85.00 | -- | -22,164.48 | -103,908.50 | 2.32 | -520.03 | 0.0075 | -- | -- | -- | 13.89 | -- | -1.13 | -- |
| IXICO PLC | 6.00m | -1.87m | 3.38m | 89.00 | -- | 0.3372 | -- | 0.5641 | -0.0386 | -0.0386 | 0.1241 | 0.2076 | 0.4725 | -- | 3.54 | 67,415.73 | -14.69 | 4.35 | -16.58 | 5.33 | 46.90 | 62.09 | -31.10 | 6.61 | -- | -- | 0.0312 | 0.00 | -22.89 | 4.32 | -214.15 | -- | 92.12 | -- |
| TheraCryf PLC | 396.00k | -3.14m | 3.54m | 9.00 | -- | 0.9687 | -- | 8.95 | -0.0114 | -0.0114 | 0.0014 | 0.0085 | 0.0858 | -- | 0.9766 | 44,000.00 | -67.93 | -42.50 | -81.69 | -46.66 | -- | -- | -792.17 | -1,482.46 | -- | -- | 0.00 | -- | -10.41 | -- | 22.41 | -- | -- | -- |
| Destiny Pharma PLC | 0.00 | -5.66m | 4.07m | 19.00 | -- | 0.4406 | -- | -- | -0.0624 | -0.0624 | 0.00 | 0.0965 | 0.00 | -- | -- | 0.00 | -60.33 | -54.32 | -67.28 | -59.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 13.02 | -- | 35.39 | -- |
| ImmuPharma PLC | 0.00 | -2.92m | 7.71m | 5.00 | -- | 7.30 | -- | -- | -0.0081 | -0.0081 | 0.00 | 0.0025 | 0.00 | -- | -- | 0.00 | -87.27 | -86.13 | -163.24 | -106.39 | -- | -- | -- | -8,634.98 | -- | -8.61 | 0.00 | -- | -- | -- | 23.26 | -- | -- | -- |
| Genflow Biosciences PLC | 0.00 | -1.63m | 7.87m | 5.00 | -- | 9.07 | -- | -- | -0.0056 | -0.0056 | 0.00 | 0.0025 | 0.00 | -- | -- | 0.00 | -88.30 | -- | -105.34 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.97 | -- | -- | -- |
| Cizzle Biotechnology Holdings PLC | 0.00 | -1.72m | 8.32m | 67.00 | -- | 5.07 | -- | -- | -0.0048 | -0.0048 | 0.00 | 0.0041 | 0.00 | -- | -- | -- | -76.69 | -144.15 | -82.81 | -167.75 | -- | -- | -- | -- | -- | -0.805 | 0.00 | -- | -- | -- | -88.27 | -- | -- | -- |
| Synairgen plc | 0.00 | -8.41m | 9.57m | 36.00 | -- | 0.7557 | -- | -- | -0.0418 | -0.0418 | 0.00 | 0.0629 | 0.00 | -- | -- | 0.00 | -44.55 | -54.01 | -51.06 | -60.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.35 | -- | -26.64 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Octopus Investments Ltd.as of 04 Jun 2021 | 3.35m | 0.00% |
| Hargreaves Lansdown Asset Management Ltd.as of 01 May 2024 | 3.30m | 0.00% |
| KW Investment Management Ltd.as of 01 May 2024 | 3.08m | 0.00% |
| Schroder Investment Management Ltd.as of 12 Mar 2021 | 2.84m | 0.00% |
| IG Markets Ltd.as of 01 May 2024 | 2.32m | 0.00% |
| HSBC Bank Plc (Market-Maker)as of 01 May 2024 | 698.00k | 0.00% |
| abrdn Investments Ltd.as of 01 May 2024 | 591.00k | 0.00% |
| HSBC Global Asset Management (UK) Ltd.as of 01 May 2024 | 581.00k | 0.00% |
| Partners Investment Co. LLPas of 11 Feb 2020 | 531.85k | 0.00% |
| James Brearley & Sons Ltd.as of 01 May 2024 | 501.00k | 0.00% |
